Pfizer/BioNTech Initiates COVID-19 Vaccine Trial In Children Below 12 Years: Reuters

  • Pfizer Inc PFEBioNTech SE BNTX will begin testing its COVID-19 vaccine in a bigger group of children under age 12 after selecting a lower dose shot in an earlier stage of the trial.
  • The study will enroll up to 4,500 children at more than 90 clinical sites, Reuters reported.
  • Based on safety, tolerability, and the immune response generated by 144 children in a Phase 1 study, Pfizer will test a dose of 10 micrograms in children between 5 and 11 years of age and 3 micrograms for the age group of 6 months to 5.
  • The vaccine has been authorized for use in children as young as 12 in Europe, the U.S., and Canada, and they receive the same dose of 30 micrograms as adults.
  • Still, researchers are studying the possibility of a link between heart inflammation and mRNA vaccines, particularly in young men. Both PFE/BNTX and Moderna Inc's MRNA vaccines are mRNA shots.
  • Last week, Israel's Health Ministry said it had found a small number of myocarditis cases observed mainly in young men who received the Pfizer vaccines. The cases were generally mild and short-lasting.
  • Price Action: PFE shares are down 0.55% at $38.78, and BNTX shares are down 6.6% at $222.47 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechGovernmentNewsHealth CareFDAGeneralBriefsCOVID-19 VaccineReuters
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!